Transplantation Proceedings
Volume 36, Issue 1 , Pages 35-37 , January 2004

Angiotensin-converting enzyme genotype is a predictive factor in the peak panel-reactive antibody response

  • A Akçay

      Affiliations

    • Department of Nephrology (A.A., F.N.Ö., S.S., Z.A.), Baskent University Faculty of Medicine, Ankara, Turkey
    • ,
  • F.N Özdemir

      Affiliations

    • Department of Nephrology (A.A., F.N.Ö., S.S., Z.A.), Baskent University Faculty of Medicine, Ankara, Turkey
    • Corresponding Author InformationAddress reprint requests to Fatma Nurhan Özdemir, MD, Başkent Üniversitesi Hastanesi, Fevzi Çakmak Cad. 10. Sok. no. 45 Bahçelievler, Ankara, Turkey.
    • ,
  • F.B Ataç

      Affiliations

    • Department of Molecular Biology (F.B.A., H.V.), Baskent University Faculty of Medicine, Ankara, Turkey
    • ,
  • S Sezer

      Affiliations

    • Department of Nephrology (A.A., F.N.Ö., S.S., Z.A.), Baskent University Faculty of Medicine, Ankara, Turkey
    • ,
  • H Verdi

      Affiliations

    • Department of Molecular Biology (F.B.A., H.V.), Baskent University Faculty of Medicine, Ankara, Turkey
    • ,
  • Z Arat

      Affiliations

    • Department of Nephrology (A.A., F.N.Ö., S.S., Z.A.), Baskent University Faculty of Medicine, Ankara, Turkey
    • ,
  • M Haberal

      Affiliations

    • Department of General Surgery (H.M.) Baskent University Faculty of Medicine, Ankara, Turkey

References 

  1. Sumitran-Holgersson S. HLA-specific alloantibodies and renal graft outcome. Nephrol Dial Transplant. 2001;16:897
  2. Cecka JM. The UNOS Scientific Renal Transplant Registry. Clin Transpl 1, 1998
  3. Fellstrom B. Nonimmune risk factors for chronic renal allograft dysfunction. Transplantation. 2001;71(Suppl):10
  4. Wolf G, Neilson EG. Angiotensin II as a renal growth factor. J Am Soc Nephrol. 1993;3:1531
  5. Lalouel JM, Rohrwasser A, Terreros D, et al.  Angiotensinogen in essential hypertension (from genetics to nephrology). J Am Soc Nephrol. 2001;12:606
  6. Hollenberg NK. Renal implications of angiotensin receptor blockers. Am J Hypertens. 2001;14:237
  7. Abdi R, Huong TTB, Zee R, et al.  Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension. Transplantation. 2001;72:726
  8. Nicod J, Richard A, Frey FJ, et al.  Recipient RAS gene variants and renal allograft function. Transplantation. 2002;73:960
  9. Haznedaroglu IC, Ozturk MA. Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system. Int J Biochem Cell Biol. 2003;35:867
  10. Rodgers KE, Xiong S, Steer R, et al.  Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells. 2000;18:287
  11. Gaston RS, Julian BA, Curtis JJ. Posttransplant erythrosis (an enigma revisited). Am J Kidney Dis. 1994;24:277
  12. Inigo P, Torregrosa JV, Campistol JM, et al.  Treatment with losartan in kidney transplant recipients with posttransplant erythrocytosis. Transplant Proc. 1999;31:2321
  13. Macdougall IC. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant. 1999;14:1836

PII: S0041-1345(03)01224-7

doi: 10.1016/j.transproceed.2003.11.013

Transplantation Proceedings
Volume 36, Issue 1 , Pages 35-37 , January 2004

Article Tools